222. Primary nephrotic syndrome
234 clinical trials,   241 drugs   (DrugBank: 78 drugs),   59 drug target genes,   185 drug target pathways
Searched query = "Primary nephrotic syndrome", "Minimal change nephrotic syndrome", "MCNS", "Membranous nephropathy", "Focal segmental glomerulosclerosis", "FSGS", "Membranoproliferative glomerulonephritis", "MPGN"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | ChiCTR-TQR-12002602 | 2009-10-09 | 2012-10-16 | The Effects of an Combinedative Treatment of with Prednisone plus and Fluvastatin on the Levels of Cholesterol and Bilirubin in the Patients with Minimal Change Nephropathy | The Effects of an Combinedative Treatment of with Prednisone plus and Fluvastatin on the Levels of Cholesterol and Bilirubin in the Patients with Minimal Change Nephropathy | Minimal change nephrotic syndrome in children | Treatment:prednisone 1~2 mg/kg/day+Fluvastatin Sodium Capsule;Control:prednisone 1~2 mg/kg/day; | Treatment center of kidney disease, 281th hospital of PLA | NULL | Completed | 4 | 12 | Both | Treatment:30;Control:30; | I (Phase 1 study) | China |